Netia Medical Technologies
Netia Medical Technologies specializes in innovative RNAi drug design platforms, enabling carrier-free RNAi drug delivery for therapeutic applications. Their mission is to develop advanced drug design solutions that target various diseases, including age-related and multiorgan disorders, with a focus on broad tissue distribution and targeting lncRNAs for cancer treatment.
Industries
health-care
medical
therapeutics
Nr. of Employees
small (1-50)
Netia Medical Technologies
Products
Single-strand RNAi drug-design platform
A drug-design platform producing guide-strand-only and sequential single-strand RNAi therapeutics that enable carrier-free systemic delivery, high target knockdown, lncRNA targeting, splice modulation, and local dosing to protected sites.
Single-strand RNAi drug-design platform
A drug-design platform producing guide-strand-only and sequential single-strand RNAi therapeutics that enable carrier-free systemic delivery, high target knockdown, lncRNA targeting, splice modulation, and local dosing to protected sites.
Services
Patent licensing and acquisition
Discussion and negotiation for acquiring or licensing patent rights covering RNAi drug-design platforms.
Patent licensing and acquisition
Discussion and negotiation for acquiring or licensing patent rights covering RNAi drug-design platforms.
Expertise Areas
- RNA interference therapeutic design
- Oligonucleotide medicinal chemistry
- Systemic and local oligonucleotide delivery
- lncRNA-targeting strategies
Key Technologies
- Single-stranded RNAi therapeutics
- Sequential RNAi (seqRNAi) delivery
- 5'-terminal nucleotide phosphorylation strategies
- 2'-O-methyl nucleotide modification